Hôpital de la Pitié Salpêtrière
Paris, France
NCT Number: NCT04923516
To determine the proportion of patients suffering from acute hepatic porphyria (AHP) from different hospital departments and referred to an internist referent for a suggestive clinical picture with a first negative etiological assessment.
Looking for future studies?
Notify Me18 year–60 year
All sexes
Observational
Paris, France
In this context, this study aims to assess the prevalence of PHA in a population of patients with a suggestive clinical picture. A better knowledge of the pathology will make it possible to better guide patients and prevent them from diagnostic wandering fraught with physical and psychological consequences.
This is an observational, ambispective, transversal, multicenter study carried out in France. The goal is to recruit a cohort that will reflect current practice. 500 patients will be recruted.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Results of dosages of Delta-aminolevulinic acid and Porphobilinogen which are performed in accordance with the current practice will be recorded
Time frame: 1 day
The diagnosis of acute hepatic porphyria is based on urine testing of the neurotoxic precursors of haem: Delta-aminolevulinic acid and Porphobilinogen. A patient will be considered to have acute hepatic porphyria (acute hepatic porphyria +) if:
Association pour la Recherche en Medecine Interne
Network
Prevalence of Acute Hepatic Porphyria in Population With Suggestive Clinical Picture
Acronym: PHA
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03338816
ALA Dehydratase Deficient Porphyria (ADP), Acute Hepatic Porphyria
Little Rock, Arkansas, United States
View Trial DetailsNCT02240784
Acute Hepatic Porphyria, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
San Francisco, California, United States
View Trial DetailsNCT04883905
Acute Hepatic Porphyria, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Birmingham, Alabama, United States
View Trial DetailsNCT05344599
Acute Hepatic Porphyria, Autonomic Nervous System Diseases
Nashville, Tennessee, United States
View Trial Details